AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
AEON Biopharma, Inc. (AEON), a Delaware corporation trading on NYSE American, filed this Current Report on Form 8-K on August 12, 2026. The filing announces financial results for the second quarter ended June 30, 2026, and includes a corporate presentation for investor relations.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2). The text of the 8-K itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced exhibits which are not included in the input text.
Material Changes
No material changes versus the prior comparable period are detailed in the body of this filing. The document indicates that the full details of the second-quarter results are available in the attached press release.
Guidance, Outlook, and Risks
Management has released a corporate presentation containing forward-looking statements. The filing explicitly notes that investors should refer to the "Forward-Looking Statements" slide within Exhibit 99.2 for important information regarding risks and contingencies. The filing states that the information in Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, net loss, and cash burn figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, regulatory milestones, and liquidity runway.
- Verify the "Forward-Looking Statements" section in the presentation for specific risk factors related to capital needs and development risks.
- Confirm the company's cash position and burn rate to assess the need for future capital raises.